HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
VMD
Viemed Healthcare, Inc.
VMD's fundamentals are strong: revenue grew 22% and free cash flow more than tripled. At 24x earnings, it's trading in line with its usual 26x. Analysts expect earnings growth, though they disagree widely on how much.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
VMD Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Healthy | |
| Strong |
VMD's revenue, profitability, cash flow and balance sheet are all currently healthy.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
VMD PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 18x | $6.92 | -24% |
| Forward | 18x | $9.11 | — |
| Current | 24x | $9.11 | — |
| Fair | 26x | $9.97 | +9.4% |
| Expensive | 36x | $13.67 | +50% |
Historical ranges are pointers, not guarantees.
VMD's PE is in its fair range at 24x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
VMD Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| Low |
VMD has the edge over HIMS on the outlook, with more favorable earnings expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
VMD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.50 | +32% |
| Q3 2026 | $0.38 | +15% |
| Q2 2026 | $0.36 | +5.9% |
| Q1 2026 | $0.37 | +23% |
| Q4 2025 | $0.37 | +32% |
| Q3 2025 | $0.33 | +27% |
| Q2 2025 | $0.34 | +48% |
| Q1 2025 | $0.30 | +20% |
| Q4 2024 | $0.28 | +12% |
VMD has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over VMD on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
VMD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $80.7M | +12% |
| Q2 2026 | $78.1M | +24% |
| Q1 2026 | $75.4M | +28% |
| Q4 2025 | $76.2M | +26% |
| Q3 2025 | $71.9M | +24% |
| Q2 2025 | $63.1M | +15% |
| Q1 2025 | $59.1M | +17% |
| Q4 2024 | $60.7M | +20% |
VMD's revenue has grown year over year for 20 quarters in a row: $81M last quarter, up 12% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 8.6% | +0.8 points |
| Q2 2026 | 5.7% | -2.4 points |
| Q1 2026 | 5.7% | -0.8 points |
| Q4 2025 | 11% | +0.4 points |
| Q3 2025 | 7.8% | -1.8 points |
| Q2 2025 | 8.1% | +1.5 points |
| Q1 2025 | 6.5% | +2.1 points |
| Q4 2024 | 11% | +0.2 points |
VMD has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over VMD on cash flow, with more consistent year-over-year improvement.
VMD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $2.9M | -73% |
| Q2 2026 | $7.4M | +80% |
| Q1 2026 | $1.4M | +$14M |
| Q4 2025 | $9.7M | +207% |
| Q3 2025 | $10.7M | +516% |
| Q2 2025 | $4.1M | +231% |
| Q1 2025 | -$12.6M | -$7.8M |
| Q4 2024 | $3.2M | -41% |
VMD generated $21M in free cash flow over the past year, about four times what it generated the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over VMD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
VMD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +66.6K shares |
| 1 year | +1.7% | +697K shares |
| 3 years | +1.9% | +772K shares |
| 5 years | +1.3% | +533K shares |
| Available history | +3.6% | +1.4M shares |
VMD has 41M diluted shares, up 1.7% from a year ago, despite $8M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $977,000 |
| Q2 2026 | $5.3M |
| Q1 2026 | $1.4M |
| Q4 2025 | — |
| Q3 2025 | $11.6M |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
VMD spent $8M buying back its own shares over the past year.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
VMD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.1x | Net Cash |
| Q2 2026 | -0.1x | Net Cash |
| Q1 2026 | -0.0x | Net Cash |
| Q4 2025 | -0.0x | Net Cash |
| Q3 2025 | 0.3x | Very low |
| Q2 2025 | -0.5x | Net Cash |
| Q1 2025 | -0.2x | Net Cash |
| Q4 2024 | -0.4x | Net Cash |
VMD has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
VMD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.9 | Neutral |
| Stochastic | 27.9 | Neutral |
VMD's weekly RSI is 45 (neutral) and its Stochastic is 28 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
VMD PE vs Healthcare Sector
| Metric | VMD | Sector median | Relative |
|---|---|---|---|
| PE | 24x | 26x | 7.3% below |
| PE % | 39 | 29 | 10 pts above |
VMD is trading at 24x earnings, in line with the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
VMD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $9.34 | 2.5% below |
| 20 week MA | $9.90 | 8% below |
| 50 week MA | $9.25 | 1.5% below |
| 100 week MA | $8.16 | 12% above |
| 200 week MA | $8.23 | 11% above |
VMD has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
VMD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $6.28 | $8.00 | +27% |
| 2021 | $8.00 | $5.59 | -30% |
| 2022 | $5.59 | $7.45 | +33% |
| 2023 | $7.45 | $7.85 | +5.4% |
| 2024 | $7.85 | $8.16 | +3.9% |
| 2025 | $8.16 | $7.30 | -11% |
| 2026 YTD | $7.30 | $9.11 | +25% |
VMD has the edge over HIMS on returns for 2026, with the stronger performance.